2018 NDAA Supports Precision Benefit Design for Pharmaceuticals
On Tuesday, December 12, 2017, the President signed the $700 billion National Defense Authorization Act for fiscal year 2018. The defense bill includes the incorporation of V-BID principles within Section 702 – Modifications of cost-sharing requirements for the TRICARE Pharmacy Benefits Program and treatment of certain pharmaceutical agents.
Sec 702 (C) (b) (1) reads:
This major policy milestone builds on growing bipartisan support and the expanded role of V-BID in public and private payers, including the recent expansion of the CMMI Medicare Advantage V-BID demonstration to 25 states and Congressional and Trump Administration efforts to allow high-deductible health plans the flexibility to provide coverage for services that manage chronic disease prior to meeting the plan deductible.
View the resources below to learn more about V-BID in TRICARE and Precision Medicine.
